Literature DB >> 18789855

The socio-economical burden of schizophrenia: a simulation of cost-offset of early intervention program in Italy.

Alessandro Serretti1, Laura Mandelli, Emanuele Bajo, Nadia Cevenini, Pietro Papili, Elisa Mori, Marco Bigelli, Domenico Berardi.   

Abstract

Schizophrenia is associated with a high familiar, social and economic burden. During the recent years early and specific intervention for first psychotic episodes has been suggested to improve the long term outcome of the disease. Despite the promising results obtained so far, early intervention is still scarcely applied. One major problem arises from the translation of research findings into stakeholder policies. In fact very few analyses of cost reductions obtained with early intervention have been reported. In the present paper we present a simulation of direct cost reduction that can be obtained with early intervention programmes. We based our analysis on available data about schizophrenia care costs in Italy and the expected cost reduction with the use of early intervention. We observed that the increase in costs due to the more intensive early intervention is largely compensated by the reduction of inpatient admissions with a reduction of direct costs of 6.01%. Despite the apparently small economic gain, early intervention offers more clinical and social benefits as it seems to be effective also in decreasing relapse rates, in improving the patients' quality of life and disability associated with psychosis and in increasing employment rates. Those indirect costs however are difficult to estimate and were not included in our model. In conclusion, our study supports the use of early intervention in schizophrenia, which could allow an outcome improvement with lower direct and indirect costs.

Entities:  

Mesh:

Year:  2008        PMID: 18789855     DOI: 10.1016/j.eurpsy.2008.07.009

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  4 in total

1.  Effectiveness of Family Intervention for Preventing Relapse in First-Episode Psychosis Until 24 Months of Follow-up: A Systematic Review With Meta-analysis of Randomized Controlled Trials.

Authors:  Miguel Camacho-Gomez; Pere Castellvi
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

Review 2.  Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Authors:  Georgia L Stevens; Gail Dawson; Jacqueline Zummo
Journal:  Early Interv Psychiatry       Date:  2015-09-25       Impact factor: 2.732

3.  Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study.

Authors:  Paolo A Cortesi; Claudio Mencacci; Ferrannini Luigi; Elvezio Pirfo; Patrizia Berto; Miriam C J M Sturkenboom; Fabiana L Lopes; Maria G Giustra; Lorenzo G Mantovani; Luciana Scalone
Journal:  BMC Psychiatry       Date:  2013-03-22       Impact factor: 3.630

4.  Claims-based proxies of patient instability among commercially insured adults with schizophrenia.

Authors:  Charles Ruetsch; Hyong Un; Heidi C Waters
Journal:  Clinicoecon Outcomes Res       Date:  2018-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.